Survival in hemodialysis in Brazil according to the source of payment for the treatment: Public Healthcare System (SUS) versus private insurance.

Ana Beatriz Lesqueves Barra Ana Paula Roque da Silva Maria Eugenia Fernandes Canziani Jocemir Ronaldo Lugon Jorge Paulo Strogoff de Matos

Published in: Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia (2023)

Patients on HD with treatment funded by the SUS have a higher adjusted risk of death when compared to those with private insurance, despite similar dialysis treatment. Factors not directly related to dialysis therapy could explain this difference.

Keyphrases

end stage renal disease
chronic kidney disease
health insurance
healthcare
peritoneal dialysis
mental health
newly diagnosed
emergency department
stem cells
ejection fraction
replacement therapy
affordable care act
prognostic factors
mesenchymal stem cells
drug induced
adverse drug